Skip to main content
R

RADIOPHARM THERANOSTICS LIMITED — Investor Relations & Filings

Ticker · RAD ISIN · AU0000181851 ASX Professional, scientific and technical activities
Open in API
Filings indexed 107 across all filing types
Latest filing 2026-04-22 Interim / Quarterly Rep…
Country AU Australia
Listing ASX RAD

About RADIOPHARM THERANOSTICS LIMITED

https://radiopharmtheranostics.com/

Radiopharm Theranostics Limited is a clinical-stage company specializing in the development of a diverse platform of radiopharmaceutical products for oncology. The company employs a theranostic strategy, integrating diagnostic imaging and targeted therapeutic agents to address various cancers with high unmet medical needs. Its pipeline features multiple proprietary assets, including PTPμ for brain tumors, αVβ6 Integrin for pancreatic and head and neck cancers, and LRRC15 for aggressive solid tumors. By utilizing radioisotopes such as Actinium-225, Lutetium-177, and Gallium-68, the company develops precision medicines designed to target specific biomarkers on cancer cells. These technologies aim to provide highly localized radiation therapy while sparing healthy tissue, advancing through clinical phases to improve outcomes for patients with complex malignancies.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 1.5MB
Interim / Quarterly Report Q3 2026
2026-04-22 English
RAD Initial Findings from Phase 1 177Lu-RAD202 Trial 3 pages 136.7KB
Regulatory Filings Classification · 1% confidence The document is an ASX regulatory announcement detailing clinical trial findings and a poster presentation at a scientific conference. It does not announce financial results, capital changes, management changes, dividends, or any regulatory filing specifically covered by other categories. It is essentially a corporate news release to the exchange, so it falls into the fallback “Regulatory Filings” category.
2026-04-19 English
RAD Completes Enrollment in Phase 2b Trial of RAD 101 2 pages 355.3KB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement regarding a clinical trial milestone (enrollment completion in a Phase 2b imaging trial) for Radiopharm Theranostics. It contains no financial results, no regulatory audit data, no share transactions, no board changes, and is not a proxy or investor presentation. It is a general corporate press release filed with the exchange that does not fit any of the specific financial report categories. Therefore it falls under the fallback “Regulatory Filings” category.
2026-04-15 English
RAD202 Phase 1 HEAT Trial Advances to Dose Level 3 2 pages 131.9KB
Regulatory Filings
2026-04-07 English
RAD and Siemens Sign Clinical Supply Agreement for RAD101 2 pages 118.2KB
Regulatory Filings
2026-04-06 English
Change of Director's Interest Notice (IT) 3 pages 241.4KB
Regulatory Filings
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.